SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-082077
Filing Date
2024-03-29
Accepted
2024-03-29 16:15:03
Documents
14
Period of Report
2024-03-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d802175d8k.htm   iXBRL 8-K 24920
2 EX-10.1 d802175dex101.htm EX-10.1 91914
  Complete submission text file 0001193125-24-082077.txt   267529

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oric-20240326.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20240326_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20240326_pre.xml EX-101.PRE 11714
17 EXTRACTED XBRL INSTANCE DOCUMENT d802175d8k_htm.xml XML 3778
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 24804268
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)